In April, another round of Warning Letters landed, this time targeting companies marketing unapproved GLP-1, dual GLP-1/GIP, and triple agonist products, many labeled research use only (RUO)
There is currently no evidence that Retatrutide with CJC-1295 and Ipamorelin provides greater weight management or metabolic benefits than Retatrutide alone
For post-cholecystectomy patients considering GLP-1 therapy, understanding your baseline metabolic healthincluding liver enzymes, lipid profiles, and pancreatic functionbecomes especially important
The bottom line Oral GLP-1s can be a real option, with real efficacy, for the right person
doi:10.1056/NEJMoa1200111 Mingrone G, Panunzi S, De Gaetano A, et al
The older we get, the less growth hormone we produce and the more our neurons degenerate